Powering Next-Gen NK Cell
Therapy with Non-Viral Delivery
Presenters:
Michael Chu, MD
Medical Oncologist, Associate Professor,
Cross Cancer Institute
Michael Chu, PhD is a clinician scientist at the Cross Cancer Institute. His research focuses on basic and translational cancer research with an emphasis on immune therapy, including monoclonal antibodies and cellular therapy. He has a wide range of clinical research where he serves as principal investigator and sub-principal investigator on multiple phase I, II, and III clinical trials.
Curtis Hodge, PhD
Co-Founder, CEO,
Nanotein Technologies, Inc
Curtis Hodge is the CEO and co-founder of Nanotein Technologies, Inc., a biotech company that develops NK and T cell reagents that address current limitations and streamline the production of cell therapies. Curtis led Nanotein to form an exclusive partnership with Sartorius to bring global access to these critically enabling next-gen reagents.
